Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation
- PMID: 18781877
- PMCID: PMC2668264
- DOI: 10.1086/591969
Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation
Abstract
Background: Invasive mold infections (IMIs) are common in individuals who have undergone hematopoietic stem cell transplantation (HSCT). We sought to determine clinical and biological risk factors for different IMIs during each period (early and late) after allogeneic HSCT.
Methods: Cases of proven and probable IMI diagnosed in HSCT recipients at the Fred Hutchinson Cancer Research Center (Seattle, WA) from 1 January 1998 through 31 December 2002 were included. Survival was estimated with Kaplan-Meier curves, and Cox regression models were used for multivariable analyses.
Results: During the study period, 1248 patients underwent allogeneic HSCT; 163 (13.1%) received a diagnosis of probable or proven IMI. The majority of cases were caused by Aspergillus species (88%). The incidence of IMI caused by other molds remained low (<2%) over the 4-year study period. Risk factors for IMI early after HSCT and late after HSCT differed, with host variables (age) and transplant variables (human leukocyte antigen match) predominating as early risk factors and other clinical complications (graft-versus-host disease and cytomegalovirus disease) predominating later. Biological risk factors that were important during all periods included multiple cytopenias (neutropenia, lymphopenia, and monocytopenia) and iron overload.
Conclusions: Risk factors for invasive aspergillosis after allogeneic HSCT are multifactorial and differ according to timing after HSCT. Increased attention should be placed on understanding the immunopathogenesis of fungal disease after HSCT.
Figures



Similar articles
-
Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation.Eur J Haematol. 2015 Mar;94(3):235-42. doi: 10.1111/ejh.12421. Epub 2014 Sep 13. Eur J Haematol. 2015. PMID: 25082161
-
Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.Transpl Infect Dis. 2018 Aug;20(4):e12897. doi: 10.1111/tid.12897. Epub 2018 May 7. Transpl Infect Dis. 2018. PMID: 29668073 Free PMC article.
-
Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study.Biol Blood Marrow Transplant. 2017 Oct;23(10):1773-1779. doi: 10.1016/j.bbmt.2017.06.012. Epub 2017 Jun 28. Biol Blood Marrow Transplant. 2017. PMID: 28668492
-
Allogeneic hematopoietic stem cell transplant recipients and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections.Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12669. Epub 2017 Mar 31. Transpl Infect Dis. 2017. PMID: 28128496 Review.
-
Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.Mycopathologia. 2006 Jul;162(1):1-15. doi: 10.1007/s11046-006-0025-x. Mycopathologia. 2006. PMID: 16830186 Review.
Cited by
-
Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.Open Forum Infect Dis. 2024 Jul 23;11(8):ofae409. doi: 10.1093/ofid/ofae409. eCollection 2024 Aug. Open Forum Infect Dis. 2024. PMID: 39135965 Free PMC article.
-
Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.Folia Microbiol (Praha). 2022 Jun;67(3):363-387. doi: 10.1007/s12223-021-00934-5. Epub 2022 Feb 26. Folia Microbiol (Praha). 2022. PMID: 35220559 Free PMC article. Review.
-
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.J Clin Microbiol. 2009 Oct;47(10):3142-6. doi: 10.1128/JCM.00940-09. Epub 2009 Aug 19. J Clin Microbiol. 2009. PMID: 19692559 Free PMC article.
-
Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.Br J Haematol. 2011 Nov;155(3):318-27. doi: 10.1111/j.1365-2141.2011.08838.x. Epub 2011 Aug 22. Br J Haematol. 2011. PMID: 21880032 Free PMC article. Clinical Trial.
-
Overlapping and distinct roles of Aspergillus fumigatus UDP-glucose 4-epimerases in galactose metabolism and the synthesis of galactose-containing cell wall polysaccharides.J Biol Chem. 2014 Jan 17;289(3):1243-56. doi: 10.1074/jbc.M113.522516. Epub 2013 Nov 20. J Biol Chem. 2014. PMID: 24257745 Free PMC article.
References
-
- Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–66. - PubMed
-
- Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis. 2003;3:156–61. - PubMed
-
- Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant. 1999;5:55–68. - PubMed
-
- Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–52. - PubMed
-
- Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical